Qarziba and Bylvay, treatments for rare diseases in children, were selected side by side as the first target drugs for the government's parallel pilot project of 'applying for permission-reimbursement evaluation-negotiation of drug price'. Qarziba is a treatment for neuroblastoma, and Bylvay is a treatment for progressive cholestatic pruritus (pruritus).

On the 26th, at a meeting with the Korea Special Press Association, the Ministry of Health and Welfare Insurance and Pharmaceuticals announced the results of the selection of the first approval-reimbursement-price combination drug as part of a plan to improve access to treatment for expensive severe diseases and strengthen benefit management.

Lee, Jeong-Hwan(junghwanss@dailypharm.com)